Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Nathan H Fowler, MD, Sven de Vos, MD, PhD, Marshall T. Schreeder, MD, John P. Leonard, MD, Ian W. Flinn, MD, PhD, Steve Coutre, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Ralph V. Boccia, MD, Jacqueline C. Barrientos, MD, Thomas E. Boyd, MD, Leanne M. Holes, Brian J. Lannutti, PhD, David Johnson, Thomas M. Jahn, MD/PhD, Langdon L Miller, MD, Wayne R Godfrey, MD

Blood (2012) 120 (21): 3645.

https://doi.org/10.1182/blood.V120.21.3645.3645

Published: 2012

Journal Articles

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).

Holbrook E Kohrt, MD, Samit Patel, Michelle Ho, Terri Owen, Ravindra Majeti, MD, PhD, Jason R. Gotlib, MD, Steve Coutre, MD, Bruno C. Medeiros, MD, Ash A Alizadeh, MD, PhD

Blood (2009) 114 (22): 1617.

https://doi.org/10.1182/blood.V114.22.1617.1617

Published: 2009

Journal Articles

A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies.

D Ball Edward, MD, Bruno C. Medeiros, MD, Larissa Balaian, PhD, Tracy Roque, Sue Corringham, RN, Richa Rajwanshi, Steve Coutre, MD, Jason R Gotlib, MD, MS, Asad Bashey, MD, PhD, Karen Messer, PhD

Blood (2009) 114 (22): 2049.

https://doi.org/10.1182/blood.V114.22.2049.2049

Published: 2009

Journal Articles

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Anjali Advani, MD, Holly Gundacker, MS, Olga Sala-Torra, MD, Jerald Radich, MD, Raymond Lai, MD, PhD, Marilyn L. Slovak, PhD, Jeffrey E Lancet, MD, Steve Coutre, MD, Robert K Stuart, MD, Martha P. Mims, MD, PhD, Patrick Stiff, MD, Frederick R. Appelbaum, MD

Blood (2009) 114 (22): 3094.

https://doi.org/10.1182/blood.V114.22.3094.3094

Published: 2009

Journal Articles

Predictive Progenitor Profiling in Chronic Myelomonocytic Leukemia.

Catriona Jamieson, MD, PhD, Jason Gotlib, MD, Steve Coutre, MD, Kevin Li, PhD, Irving Weissman, MD

Blood (2004) 104 (11): 4739.

https://doi.org/10.1182/blood.V104.11.4739.4739

Published: 2004

NARROW

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).

A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies.

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Predictive Progenitor Profiling in Chronic Myelomonocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).

A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies.

Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.

Predictive Progenitor Profiling in Chronic Myelomonocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only